Found: 49
Select item for more details and to access through your institution.
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 46, doi. 10.1111/dom.14842
- By:
- Publication type:
- Article
Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1956, doi. 10.1111/dom.14401
- By:
- Publication type:
- Article
Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1823, doi. 10.1111/dom.14400
- By:
- Publication type:
- Article
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1588, doi. 10.1111/dom.14372
- By:
- Publication type:
- Article
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 39, doi. 10.1111/dom.14180
- By:
- Publication type:
- Article
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2276, doi. 10.1111/dom.14150
- By:
- Publication type:
- Article
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 11, p. 2474, doi. 10.1111/dom.13830
- By:
- Publication type:
- Article
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 4, p. 1027, doi. 10.1111/dom.13631
- By:
- Publication type:
- Article
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 520, doi. 10.1111/dom.13103
- By:
- Publication type:
- Article
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 389, doi. 10.1111/dom.13083
- By:
- Publication type:
- Article
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/ mL added to oral antidiabetes agents in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 11, p. 1546, doi. 10.1111/dom.12966
- By:
- Publication type:
- Article
Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy.
- Published in:
- Clinical Drug Investigation, 2013, v. 33, n. 10, p. 707, doi. 10.1007/s40261-013-0107-8
- By:
- Publication type:
- Article
Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 8, p. 1861, doi. 10.1007/s13300-020-00874-2
- By:
- Publication type:
- Article
In vitro relationship of CD4 cells from type I diabetic patients and xenogeneic beta-cell membranes.
- Published in:
- 1989
- By:
- Publication type:
- journal article
Cytoadherence of lymphocytes from type I diabetic subjects to insulin-secreting cells. Marker of anti-beta-cell cellular immunity.
- Published in:
- 1987
- By:
- Publication type:
- journal article
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
- Published in:
- Vascular Health & Risk Management, 2007, v. 3, n. 4, p. 355
- By:
- Publication type:
- Article
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
- Published in:
- 2007
- By:
- Publication type:
- journal article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-791-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
1590-P: Effects of Second-Line Metformin Combination Therapies on Weight, HbA1c, and Risk of Hypoglycemia over 3 Years: The DISCOVER Study.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1590-P
- By:
- Publication type:
- Article
1628-P: Changes in HbA<sub>1c</sub> and Treatment in the Second Year following Initiation of Second-Line Therapy in People with T2D—The Global DISCOVER Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1628-P
- By:
- Publication type:
- Article
1448-P: Potential Overtreatment of Older Patients with T2D: The Global DISCOVER Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1448-P
- By:
- Publication type:
- Article
131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-131-LB
- By:
- Publication type:
- Article
1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1210-P
- By:
- Publication type:
- Article
207-LB: Type 2 Diabetes and Heart Failure: Insights from the DISCOVER Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-207-LB
- By:
- Publication type:
- Article
Effects of Long-term Treatment with Pioglitazone on Lipid Levels in Patients Receiving Statin Therapy at Baseline in the PROactive Study.
- Published in:
- Diabetes, 2007, v. 56, p. A237
- By:
- Publication type:
- Article
A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency.
- Published in:
- European Journal of Endocrinology, 2009, v. 161, n. 1, p. 195, doi. 10.1530/EJE-09-0100
- By:
- Publication type:
- Article
The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 5, p. 1147, doi. 10.1007/s13300-017-0311-2
- By:
- Publication type:
- Article
Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study.
- Published in:
- Diabetes Therapy, 2016, v. 7, n. 3, p. 537, doi. 10.1007/s13300-016-0185-8
- By:
- Publication type:
- Article
Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19).
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2010, v. 95, n. 5, p. 2163, doi. 10.1210/jc.2009-1974
- By:
- Publication type:
- Article
Effect of Low-Density Lipoprotein Apheresis on Kinetics of Apolipoprotein B in Heterozygous Familial Hypercholesterolemia.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2001, v. 86, n. 4, p. 1679, doi. 10.1210/jcem.86.4.7428
- By:
- Publication type:
- Article
<sup>131</sup>I-6β-Iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas [This work ].
- Published in:
- Clinical Endocrinology, 1996, v. 44, n. 5, p. 587, doi. 10.1046/j.1365-2265.1996.720541.x
- By:
- Publication type:
- Article
Type 2 diabetes and heart failure: insights from the global DISCOVER study.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 2, p. 1711, doi. 10.1002/ehf2.13235
- By:
- Publication type:
- Article
Glucose Tolerance in Viral Hepatitis.
- Published in:
- Diabetes, 1978, v. 27, n. 6, p. 661, doi. 10.2337/diab.27.6.661
- By:
- Publication type:
- Article
Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials.
- Published in:
- Fundamental & Clinical Pharmacology, 2007, v. 21, n. s2, p. 19, doi. 10.1111/j.1472-8206.2007.00533.x
- By:
- Publication type:
- Article
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin–angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
- Published in:
- Journal of Diabetes, 2010, v. 2, n. 3, p. 212, doi. 10.1111/j.1753-0407.2010.00082.x
- By:
- Publication type:
- Article
Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study.
- Published in:
- Diabetes Care, 2014, v. 37, n. 1, p. 134, doi. 10.2337/dc13-0695
- By:
- Publication type:
- Article
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 3, p. 498, doi. 10.2337/dc12-0709
- By:
- Publication type:
- Article
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
- Published in:
- 2007
- By:
- Publication type:
- journal article
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease.
- Published in:
- Diabetes Care, 2007, v. 30, n. 11, p. 2773, doi. 10.2337/dc07-0717
- By:
- Publication type:
- Article
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone.
- Published in:
- Diabetes Care, 2006, v. 29, n. 12, p. 2638, doi. 10.2337/dc06-0706
- By:
- Publication type:
- Article
The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
- Published in:
- 2004
- By:
- Publication type:
- journal article
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
- Published in:
- 2004
- By:
- Publication type:
- journal article